Phenylephrine Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	0.01-0.1 mg/kg	As needed (bolus) or continuous rate infusion (CRI) at 0.1-0.5 mcg/kg/min	Duration: During anesthesia or as needed Notes: Titrate to effect; monitor blood pressure.
Cat	IV	0.01-0.1 mg/kg	As needed (bolus) or CRI at 0.1-0.5 mcg/kg/min	Duration: During anesthesia or as needed Notes: Titrate to effect; monitor blood pressure.
Horse	IV	0.01-0.02 mg/kg	As needed (bolus) or CRI at 0.1-0.5 mcg/kg/min	Duration: During anesthesia or as needed Notes: Titrate to effect; monitor blood pressure.
Cattle	IV	0.01-0.02 mg/kg	As needed	Duration: During anesthesia or as needed Notes: Titrate to effect; monitor blood pressure.
Small Ruminants	IV	0.01-0.02 mg/kg	As needed	Duration: During anesthesia or as needed Notes: Titrate to effect; monitor blood pressure.
Dog and Cat	Ophthalmic (topical)	1-2 drops of 2.5% or 10% solution	Once for mydriasis	Duration: Single use Notes: For ophthalmic examination; may cause local irritation.
Horse	Ophthalmic (topical)	1-2 drops of 2.5% or 10% solution	Once for mydriasis	Duration: Single use Notes: For ophthalmic examination.
Dog	Intracavernosal	0.5-1 mg	Once	Duration: Single use Notes: For treatment of priapism; use with caution.

Clinical Indications & Species Uses

General Indications

Vasopressor for hypotensive states
Topical nasal decongestant
Mydriatic agent

Dog (Canine)

Treatment of hypotension during anesthesia
Nasal decongestant (topical)
Mydriatic for ophthalmic examination
Treatment of priapism (intracavernosal injection)

Cat (Feline)

Treatment of hypotension during anesthesia
Nasal decongestant (topical)
Mydriatic for ophthalmic examination

Horse (Equine)

Treatment of hypotension during anesthesia
Treatment of nasal congestion (topical)
Mydriatic for ophthalmic examination

Cattle (Bovine)

Treatment of hypotension during anesthesia
Nasal decongestant (topical)

Small Ruminants (Sheep / Goat)

Treatment of hypotension during anesthesia
Nasal decongestant (topical)

Rabbit & Small Mammals

Mydriatic for ophthalmic examination
Nasal decongestant (topical)

Exotic & Other Species

Mydriatic for ophthalmic examination in some species

Pharmacology & Mechanism of Action

Drug Class: Sympathomimetic | Pharmacological Group: Alpha-1 Adrenergic Agonist

Mechanism of Action: Phenylephrine is a direct-acting sympathomimetic amine that primarily stimulates alpha-1 adrenergic receptors. Activation of these receptors on vascular smooth muscle causes vasoconstriction, leading to increased systemic vascular resistance and elevated blood pressure. It has minimal beta-adrenergic activity, so it does not significantly increase heart rate or contractility. In the eye, it causes mydriasis by contracting the radial muscle of the iris. It also acts as a nasal decongestant by constricting nasal mucosal blood vessels.

Pharmacodynamics: Phenylephrine produces dose-dependent increases in systolic and diastolic blood pressure, with reflex bradycardia possible. It increases peripheral vascular resistance and may reduce cardiac output. In the eye, it produces mydriasis within 10-30 minutes after topical application, lasting 4-6 hours. As a nasal decongestant, it reduces nasal congestion within minutes, with effects lasting up to 4 hours. It may also be used as a hemostatic agent due to its vasoconstrictive properties.

⚡ Pharmacokinetics Summary

Absorption: Phenylephrine is poorly absorbed orally due to first-pass metabolism in the gut and liver. After oral administration, bioavailability is low (approximately 38%). It is well absorbed from the nasal mucosa and conjunctival sac. After intravenous administration, onset of action is immediate.

Distribution: Phenylephrine is widely distributed throughout the body. It crosses the placenta but is not known to cross the blood-brain barrier significantly. It is not highly protein-bound (approximately 95% bound to albumin).

Metabolism: Phenylephrine is metabolized primarily in the liver by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). It undergoes extensive first-pass metabolism when given orally.

Excretion: Phenylephrine and its metabolites are excreted primarily in the urine. Approximately 80% of a dose is excreted within 24 hours, mostly as inactive metabolites.

Half-Life: The elimination half-life is approximately 2-3 hours in dogs and cats. In horses, the half-life is about 1.5 hours.

Bioavailability: Oral bioavailability is low (about 38%) due to first-pass metabolism. Bioavailability after topical ocular or nasal administration is variable but generally low systemically.

Protein Binding: Approximately 95% protein-bound.

Available Formulations & Strengths

Injectable Solution 10 mg/mL (1%) (IV, IM, SC)

Ophthalmic Solution 2.5%, 10% (Ophthalmic (topical))

Nasal Spray/Drops 0.25%, 0.5%, 1% (Intranasal)

Oral Tablet 10 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to phenylephrine or any component
Severe hypertension
Ventricular tachycardia
Concurrent use with MAO inhibitors (within 14 days)
Angle-closure glaucoma (for ophthalmic use)
Use as a nasal decongestant in patients with cardiovascular disease

Warnings & Clinical Precautions:

Use with caution in patients with hyperthyroidism, diabetes, or cardiovascular disease
May cause reflex bradycardia; monitor heart rate
Extravasation may cause tissue necrosis; administer IV carefully
In horses, may cause colic due to vasoconstriction of splanchnic vessels
Ophthalmic use may cause systemic absorption; use with caution in patients with cardiovascular disease
Nasal decongestants should not be used for more than 3-5 days to avoid rebound congestion
In food animals, observe withdrawal times

Adverse Effects & Reactions

Common:

Reflex bradycardia
Hypertension
Tachycardia (rare)
Local irritation at application site
Nasal stinging or burning

Serious / Severe:

Arrhythmias
Tissue necrosis if extravasated
Pulmonary edema (with overdose)
Cerebral hemorrhage (with severe hypertension)
Rebound nasal congestion

Rare:

Allergic reactions
Corneal toxicity with ophthalmic use
Systemic absorption leading to hypertension and tachycardia

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
MAO inhibitors	Severe hypertensive crisis	High
Beta-blockers	Unopposed alpha-adrenergic activity leading to severe hypertension	High
Tricyclic antidepressants	Potentiation of vasopressor effects	Moderate
Ergot alkaloids	Additive vasoconstriction	Moderate
Inhalational anesthetics (e.g., halothane)	Increased risk of arrhythmias	Moderate
Oxytocin	Additive vasoconstriction and hypertension	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypertension
Reflex bradycardia
Ventricular arrhythmias
Pulmonary edema
Cerebral hemorrhage
Seizures
Tissue necrosis at injection site

Emergency Treatment Protocol: Discontinue the drug immediately. Supportive care: administer alpha-adrenergic blockers (e.g., phentolamine) for severe hypertension. For bradycardia, atropine may be used. Control arrhythmias with appropriate antiarrhythmics. Provide oxygen and ventilatory support if pulmonary edema occurs. Treat extravasation with local infiltration of phentolamine (5-10 mg in 10-15 mL saline).

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days🥚 Eggs: 0 days

Phenylephrine is not approved for use in food animals in many countries. If used extra-label, follow local regulations and consult FARAD for specific withdrawal times. Generally, a withdrawal time of 0 days is suggested for meat and milk, but due to lack of data, a conservative withdrawal period may be recommended.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), protect from light

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from freezing. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; human-approved products may be used extra-label in animals.

Extra-Label (Off-Label) Use: In the US, phenylephrine is not FDA-approved for veterinary use in food animals. Extra-label use in food animals is permitted under AMDUCA with a valid veterinary-client-patient relationship, and withdrawal times must be established by a veterinarian. For companion animals, extra-label use is common.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Phenylephrine is a valuable vasopressor in veterinary anesthesia, particularly for managing hypotension. It is often used as a continuous rate infusion to maintain blood pressure during anesthesia. In ophthalmic practice, it is used to produce mydriasis for fundic examination, but it may not be as effective as atropine in some species. As a nasal decongestant, it is used topically for short-term relief of congestion. Due to its alpha-1 selectivity, it is less likely to cause tachycardia compared to epinephrine. However, careful monitoring of blood pressure and heart rate is essential. In horses, phenylephrine should be used with caution due to the risk of colic. For food animals, extra-label use requires careful consideration of withdrawal times.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)